This company listing is no longer active
9 Meters Biopharma Crecimiento futuro
Future controles de criterios 2/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for 9 Meters Biopharma.
Información clave
41.4%
Tasa de crecimiento de los beneficios
39.9%
Tasa de crecimiento del BPA
Crecimiento de los beneficios de Pharmaceuticals | 19.4% |
Tasa de crecimiento de los ingresos | 56.6% |
Rentabilidad financiera futura | n/a |
Cobertura de analistas | Low |
Última actualización | 30 May 2023 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Previsiones de crecimiento de beneficios e ingresos
Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
---|---|---|---|---|---|
12/31/2025 | N/A | -43 | N/A | N/A | 2 |
12/31/2024 | N/A | -41 | N/A | N/A | 3 |
12/31/2023 | 3 | -43 | N/A | N/A | 4 |
3/31/2023 | N/A | -46 | -37 | -37 | N/A |
12/31/2022 | N/A | -44 | -37 | -37 | N/A |
9/30/2022 | N/A | -41 | -35 | -35 | N/A |
6/30/2022 | N/A | -46 | -36 | -34 | N/A |
3/31/2022 | N/A | -43 | -36 | -33 | N/A |
12/31/2021 | N/A | -37 | -32 | -29 | N/A |
9/30/2021 | N/A | -32 | -30 | -28 | N/A |
6/30/2021 | N/A | -27 | -24 | -24 | N/A |
3/31/2021 | N/A | -63 | -26 | -23 | N/A |
12/31/2020 | N/A | -61 | -23 | -19 | N/A |
9/30/2020 | N/A | -65 | -19 | -16 | N/A |
6/30/2020 | N/A | -66 | -19 | -16 | N/A |
3/31/2020 | N/A | -26 | -16 | -16 | N/A |
12/31/2019 | N/A | -27 | -18 | -18 | N/A |
9/30/2019 | N/A | -22 | -17 | -17 | N/A |
6/30/2019 | N/A | -14 | -17 | -17 | N/A |
3/31/2019 | N/A | -14 | -12 | -12 | N/A |
12/31/2018 | N/A | -24 | -15 | -15 | N/A |
9/30/2018 | N/A | -22 | -15 | -15 | N/A |
6/30/2018 | N/A | -24 | -12 | -12 | N/A |
3/31/2018 | N/A | -23 | -11 | -11 | N/A |
12/31/2017 | N/A | -12 | -5 | -5 | N/A |
9/30/2017 | N/A | -11 | -4 | -4 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: 2Q3A is forecast to remain unprofitable over the next 3 years.
Beneficios vs. Mercado: 2Q3A is forecast to remain unprofitable over the next 3 years.
Beneficios de alto crecimiento: 2Q3A is forecast to remain unprofitable over the next 3 years.
Ingresos vs. Mercado: 2Q3A's revenue (56.6% per year) is forecast to grow faster than the German market (3.3% per year).
Ingresos de alto crecimiento: 2Q3A's revenue (56.6% per year) is forecast to grow faster than 20% per year.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Insufficient data to determine if 2Q3A's Return on Equity is forecast to be high in 3 years time